Neurocrine (NASDAQ: NBIX) CEO exercises options and sells shares under 10b5-1 plan

Q: What insider transaction did NBIX CEO Kyle Gano report on January 16, 2026?

Kyle Gano, Chief Executive Officer and director of Neurocrine Biosciences (NBIX) , reported exercising stock options and selling common shares on January 16, 2026 . He exercised non-qualified and incentive stock options with an exercise price of $35.99 per share and then sold the resulting common shares in market transactions.

Q: How many Neurocrine Biosciences shares does the NBIX CEO own after this Form 4?

After the reported transactions, Kyle Gano directly owned 140,407 shares of Neurocrine Biosciences common stock. This amount is shown in the Form 4 as the number of securities beneficially owned following the reported transactions.

Q: What stock options did the NBIX CEO exercise and at what price?

On January 16, 2026 , the CEO exercised a Non-Qualified Stock Option and an Incentive Stock Option , each with an exercise price of $35.99 per share. The non-qualified option covered 34,588 underlying shares, and the incentive option covered 1,812 underlying shares, all for Neurocrine Biosciences common stock.

Q: At what prices did the NBIX CEO sell Neurocrine Biosciences shares?

The Form 4 reports that 34,588 shares were sold at a weighted average price of $132.7044 per share in trades within a range of $131.42 to $133.98 . Another 1,812 shares were sold at a weighted average price of $132.7143 per share in trades within a range of $131.49 to $133.79 .

Q: When were the NBIX CEO stock options granted and when were they set to expire?

The Form 4 explains that the options exercised on January 16, 2026 were granted on February 5, 2016 . They vested in 48 equal monthly installments beginning on March 5, 2016 and were due to expire on February 5, 2026 .

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Neurocrine Biosciences' Chief Executive Officer Kyle Gano reported option exercises and related stock sales. On January 16, 2026, he exercised non-qualified stock options and incentive stock options to acquire 34,588 and 1,812 shares of common stock, respectively, at an exercise price of $35.99 per share. On the same date, he sold 34,588 shares at a weighted average price of $132.7044 per share and 1,812 shares at a weighted average price of $132.7143 per share under a pre-established Rule 10b5-1 trading plan adopted on May 20, 2025. After these transactions, he directly owned 140,407 shares of Neurocrine Biosciences common stock. The exercised options were granted on February 5, 2016 and were scheduled to expire on February 5, 2026.

Insights

CEO exercised near-expiry options and sold shares under a Rule 10b5-1 plan, ending with 140,407 directly owned shares.

The CEO of Neurocrine Biosciences, Kyle Gano, exercised non-qualified and incentive stock options with an exercise price of $35.99 per share that were originally granted on February 5, 2016 and set to expire on February 5, 2026. The exercises converted 34,588 and 1,812 options into common shares, and both option positions are now shown as having 0 derivative securities remaining.

On the same January 16, 2026, he sold the same numbers of common shares in broker-handled trades at weighted average prices of $132.7044 and $132.7143 per share. Footnotes state these were multiple transactions within price ranges from $131.42 to $133.98 and from $131.49 to $133.79, executed under a Rule 10b5-1 trading plan adopted on May 20, 2025, and that company policy restricts modifying such plans after adoption.

Following the transactions, Gano directly owned 140,407 shares of common stock. The filing describes routine option exercises ahead of expiration combined with pre-planned sales, which is typical for monetizing equity compensation while maintaining a remaining share stake.

Insider Trade Summary

Net Seller: 36,400 shares ($4,830,458)

Net Sell 6 txns

Insider Gano Kyle

Role Chief Executive Officer

Sold 36,400 shs ($4.83M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	34,588	$0.00	--
Exercise	Incentive Stock Option	1,812	$0.00	--
Exercise	Common Stock	34,588	$35.99	$1.24M
Sale	Common Stock	34,588	$132.7044	$4.59M
Exercise	Common Stock	1,812	$35.99	$65K
Sale	Common Stock	1,812	$132.7143	$240K

Holdings After Transaction: Non-Qualified Stock Option — 0 shares (Direct); Incentive Stock Option — 0 shares (Direct); Common Stock — 174,995 shares (Direct)

Footnotes (1)

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.

Form 4 Insider Transactions: What Each Field Means →

01/20/2026 - 06:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gano Kyle

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/16/2026		M		34,588	A	$35.99	174,995	D
Common Stock	01/16/2026		S⁽¹⁾		34,588	D	$132.7044⁽²⁾	140,407	D
Common Stock	01/16/2026		M		1,812	A	$35.99	142,219	D
Common Stock	01/16/2026		S⁽¹⁾		1,812	D	$132.7143⁽³⁾	140,407	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option	$35.99	01/16/2026		M			34,588	⁽⁴⁾	02/05/2026	Common Stock	34,588	$0	0	D
Incentive Stock Option	$35.99	01/16/2026		M			1,812	⁽⁴⁾	02/05/2026	Common Stock	1,812	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

4. The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX CEO Kyle Gano report on January 16, 2026?

Kyle Gano, Chief Executive Officer and director of Neurocrine Biosciences (NBIX), reported exercising stock options and selling common shares on January 16, 2026. He exercised non-qualified and incentive stock options with an exercise price of $35.99 per share and then sold the resulting common shares in market transactions.

How many Neurocrine Biosciences shares does the NBIX CEO own after this Form 4?

After the reported transactions, Kyle Gano directly owned 140,407 shares of Neurocrine Biosciences common stock. This amount is shown in the Form 4 as the number of securities beneficially owned following the reported transactions.

What stock options did the NBIX CEO exercise and at what price?

On January 16, 2026, the CEO exercised a Non-Qualified Stock Option and an Incentive Stock Option, each with an exercise price of $35.99 per share. The non-qualified option covered 34,588 underlying shares, and the incentive option covered 1,812 underlying shares, all for Neurocrine Biosciences common stock.

At what prices did the NBIX CEO sell Neurocrine Biosciences shares?

The Form 4 reports that 34,588 shares were sold at a weighted average price of $132.7044 per share in trades within a range of $131.42 to $133.98. Another 1,812 shares were sold at a weighted average price of $132.7143 per share in trades within a range of $131.49 to $133.79.

Was the NBIX CEO sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the disposition was effected by a broker pursuant to instructions in a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2025, and notes that issuer policy restricts the reporting person from amending or modifying any such plan after adoption.

When were the NBIX CEO stock options granted and when were they set to expire?

The Form 4 explains that the options exercised on January 16, 2026 were granted on February 5, 2016. They vested in 48 equal monthly installments beginning on March 5, 2016 and were due to expire on February 5, 2026.